



JC07 Rec'd PCT/PTO 15 APR 2005 ^{ADCT}

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: TANIKAWA =1

In re Application of:)	Conf. No.: 7565
)	
Masahiko TANIKAWA et al)	Art Unit: 1645
)	
Appln. No.: 10/524,019 ✓)	Examiner:
)	
Filing Date: August 23, 2003)	Washington, D.C.
371(c) Date:)	
)	
For: METHOD FOR STABILIZING)	April 15, 2005
PROTEIN SOLUTION)	
FORMULATIONS)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop Amendments
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application; and before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

[] A. Document(s) _____ is/are deemed substantially cumulative to document(s) _____, and, in accordance with 37 CFR §1.98(c), a copy of each of the former document(s) is not enclosed.

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

[X] 3. Documents AB-AH, AM, AW, and AZ-BC are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of each document AB-AH, AM, AW, and AZ-BC (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[X] For documents AH, a corresponding English-language patent or published application (ref AI) is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the

non-English-language document with its
corresponding English-language document.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] 5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Sheridan Neimark
Registration No. 20,520

:jaa

G:\BN\Y\YUAS\Tanikawa1\Pto\ids 15ap05.doc
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/524,019
Filing Date	August 26, 2003
First Named Inventor	Masahiko TANIKAWA et al
Group Art Unit	1645
Confirmation No.	7565
Attorney Docket Number	TANIKAWA =1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	AA	EP	0 239 400 B1	09-30-1987	MEDICAL RESEARCH COUNCIL		
	AB	JP	58-201994 A	11-25-1983	HAGIWARA HIDEAKI		Abs
	AC	JP	61-12288 A	01-20-1986			Trans
	AD	JP	1-59878 B2	12-20-1989	HAGIWARA HIDEAKI		Abs
	AE	JP	08-151398 A	06-11-1996	AMGEN		Abs
	AF	JP	11-092399 A	04-06-1999	CHUGAI PHARMACEUT CO LTD		Abs
	AG	JP	2001-503781 A	03-21-2001			Trans
	AH	JP	08-506023 A	07-02-1996			Trans
	AI	WO	95/05465 A1	02-23-1995	AMGEN		
	AJ	WO	90/12874 A2	11-01-1990	GENETICS INSTITUTE, INC.		
	AK	WO	92/01047 A1	01-23-1992	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED; MEDICAL RESEARCH COUNCIL		
	AL	WO	92/03918 A1	03-19-1992	GENPHARM INTERNATIONAL INC.		
	AM	WO	92/19759 A1	11-12-1992	CHUGAI PHARMACEUTICAL CO., LTD.		Abs
	AN	WO	92/20791 A1	11-26-1992	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED; MEDICAL RESEARCH COUNCIL		
	AO	WO	93/06213 A1	04-01-1993	MEDICAL RESEARCH COUNCIL; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED		
	AP	WO	93/11236 A1	06-10-1993	MEDICAL RESEARCH COUNCIL; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED		
	AQ	WO	93/12227 A1	06-24-1993	GENPHARM INTERNATIONAL, INC.		
	AR	WO	93/19172 A1	09-30-1993	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED; MEDICAL RESEARCH COUNCIL		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

(use as many sheets as necessary)

Sheet	2
-------	---

2

of

3

Complete if Known

Application Number

10/524,019

Filing Date

August 23, 2003

First Named Inventor

Masahiko TANIKAWA et al

Group Art Unit

1645

Confirmation No.

7565

Attorney Docket Number

TANIKAWA =1

[illegible]

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3
-------	---

3

of

3

Complete if Known

Application Number

10/524,019

Filing Date

August 23, 2003

First Named Inventor

Masahiko TANIKAWA et al

Group Art Unit

1645

Confirmation No.

7565

Attorney Docket Number

TANIKAWA =1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.